View in EDS

MicroRNA dynamics and their link to platelet function following acute ST-segment elevation myocardial infarction.

Saved in:
Bibliographic Details
Title: MicroRNA dynamics and their link to platelet function following acute ST-segment elevation myocardial infarction.
Authors: Pedersen OB; Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark. Electronic address: olihped@gmail.com., Grove EL; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark., Kristensen SD; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark., Pasalic L; Institute of Clinical Pathology and Medical Research, Westmead Hospital, NSW Health Pathology, Sydney, Australia; Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia., Hvas AM; Faculty of Health, Aarhus University, Aarhus, Denmark., Nissen PH; Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Source: Thrombosis research [Thromb Res] 2025 Dec; Vol. 256, pp. 109518. Date of Electronic Publication: 2025 Oct 20.
Publication Type: Journal Article
Language: English
Journal Info: Publisher: Pergamon Press Country of Publication: United States NLM ID: 0326377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-2472 (Electronic) Linking ISSN: 00493848 NLM ISO Abbreviation: Thromb Res Subsets: MEDLINE
Imprint Name(s): Original Publication: Elmsford, N. Y., Pergamon Press.
MeSH Terms: MicroRNAs*/blood , MicroRNAs*/genetics , ST Elevation Myocardial Infarction*/blood , ST Elevation Myocardial Infarction*/genetics , ST Elevation Myocardial Infarction*/drug therapy , Blood Platelets*/metabolism , Blood Platelets*/drug effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Function Tests ; Platelet Aggregation ; Percutaneous Coronary Intervention
Abstract: Competing Interests: Declaration of competing interest None related to the present study. The authors report the following general conflict. ELG has received speaker honoraria or consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Novo Nordisk, Lundbeck Pharma and Organon. He is investigator in clinical studies sponsored by AstraZeneca, Idorsia or Bayer and has received unrestricted research grants from Boehringer Ingelheim. SDK is coordinating national investigator in a clinical trial sponsored by Idorsia and has received lecture fees from Chiesi. OBP, AMH, PHN and LP have no conflicts to declare.
Background: Reduced effect of antiplatelet therapy has been observed in patients with ST-segment elevation myocardial infarction (STEMI). MicroRNA (miR) expression may serve as biomarkers for platelet function and the effect of antiplatelet therapy.
Aim: In acute STEMI patients, we investigated changes in miR expression from the acute event to a more stable phase, and evaluated their association with platelet function at both time points to assess their potential as biomarkers of antiplatelet therapy efficacy.
Methods: Patients admitted with acute STEMI for primary percutaneous coronary intervention were included and treated according to guidelines. Samples were collected within 24 h after admission and at 2-3 months after enrolment. Expression of candidate miRs, platelet reactivity markers evaluated by flow cytometry, platelet impedance aggregometry and serum thromboxane B 2 were measured at both time points.
Results: Samples were obtained in 44 STEMI patients. Two miRs (miR-15a-5p and miR-21-5p) showed lower, whereas five (miR-26b-5p, miR-126-3p, miR-150-5p, miR-223-3p and miR-423-5p) showed higher expression at follow-up than at baseline. At baseline, miR-26b-5p expression consistently correlated with the expression of the fibrinogen receptor on activated platelets, across different agonists (rho: from 0.29 to 0.32, p < 0.05). At follow-up, miR-93-5p expression was associated with platelet aggregation using various agonists (rho: from -0.39 to -0.47, p < 0.02).
Conclusions: Seven miRs were differentially expressed at follow-up compared to baseline. Several miRs were linked to platelet function at baseline and follow-up, suggesting that a single miR may not be sufficient as a biomarker for platelet function and the effect of antiplatelet therapy.
(Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Contributed Indexing: Keywords: Acute myocardial infarction; Platelet activation; Platelet function tests; microRNAs
Substance Nomenclature: 0 (MicroRNAs)
0 (Platelet Aggregation Inhibitors)
Entry Date(s): Date Created: 20251023 Date Completed: 20251123 Latest Revision: 20251123
Update Code: 20251124
DOI: 10.1016/j.thromres.2025.109518
PMID: 41129894
Database: MEDLINE
Description
Abstract:Competing Interests: Declaration of competing interest None related to the present study. The authors report the following general conflict. ELG has received speaker honoraria or consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Novo Nordisk, Lundbeck Pharma and Organon. He is investigator in clinical studies sponsored by AstraZeneca, Idorsia or Bayer and has received unrestricted research grants from Boehringer Ingelheim. SDK is coordinating national investigator in a clinical trial sponsored by Idorsia and has received lecture fees from Chiesi. OBP, AMH, PHN and LP have no conflicts to declare.<br />Background: Reduced effect of antiplatelet therapy has been observed in patients with ST-segment elevation myocardial infarction (STEMI). MicroRNA (miR) expression may serve as biomarkers for platelet function and the effect of antiplatelet therapy.<br />Aim: In acute STEMI patients, we investigated changes in miR expression from the acute event to a more stable phase, and evaluated their association with platelet function at both time points to assess their potential as biomarkers of antiplatelet therapy efficacy.<br />Methods: Patients admitted with acute STEMI for primary percutaneous coronary intervention were included and treated according to guidelines. Samples were collected within 24 h after admission and at 2-3 months after enrolment. Expression of candidate miRs, platelet reactivity markers evaluated by flow cytometry, platelet impedance aggregometry and serum thromboxane B <subscript>2</subscript> were measured at both time points.<br />Results: Samples were obtained in 44 STEMI patients. Two miRs (miR-15a-5p and miR-21-5p) showed lower, whereas five (miR-26b-5p, miR-126-3p, miR-150-5p, miR-223-3p and miR-423-5p) showed higher expression at follow-up than at baseline. At baseline, miR-26b-5p expression consistently correlated with the expression of the fibrinogen receptor on activated platelets, across different agonists (rho: from 0.29 to 0.32, p &lt; 0.05). At follow-up, miR-93-5p expression was associated with platelet aggregation using various agonists (rho: from -0.39 to -0.47, p &lt; 0.02).<br />Conclusions: Seven miRs were differentially expressed at follow-up compared to baseline. Several miRs were linked to platelet function at baseline and follow-up, suggesting that a single miR may not be sufficient as a biomarker for platelet function and the effect of antiplatelet therapy.<br /> (Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.)
ISSN:1879-2472
DOI:10.1016/j.thromres.2025.109518